Subtopic Deep Dive
Neurological Manifestations of TSC
Research Guide
What is Neurological Manifestations of TSC?
Neurological manifestations of tuberous sclerosis complex (TSC) encompass cortical tubers, subependymal nodules, epilepsy, and neurodevelopmental disorders including autism spectrum disorder driven by TSC1/TSC2 mutations.
These manifestations affect over 80% of TSC patients, with epilepsy occurring in nearly all cases (Krueger et al., 2013, 832 citations). Cortical tubers and subependymal nodules detected via MRI contribute to epileptogenesis and cognitive impairment (Meikle et al., 2007, 455 citations). mTOR pathway dysregulation underlies neuronal dysplasia and seizure activity (Orlova and Crino, 2009, 399 citations).
Why It Matters
Neurological features drive 90% of TSC morbidity, with refractory epilepsy causing intellectual disability in 50% of patients (Northrup et al., 2021, 630 citations). Everolimus reduces seizure frequency by 40% in treatment-resistant cases, improving quality of life (French et al., 2016, 722 citations; Krueger et al., 2013, 380 citations). Preemptive antiepileptic therapy in high-risk infants lowers mental retardation risk from 70% to 20% (Jóźwiak et al., 2011, 304 citations). Mouse models reveal mTOR inhibitors rescue neuronal survival, guiding precision therapies (Meikle et al., 2008, 499 citations).
Key Research Challenges
Refractory Epilepsy Management
Over 60% of TSC epilepsy resists standard antiepileptics due to multifocal tubers (Holmes and Stafstrom, 2007, 272 citations). Everolimus shows 40% response but lacks predictors of efficacy (Krueger et al., 2013, 380 citations). Surgical resection targets remain imprecise amid widespread tubers.
Cortical Tuber Epileptogenesis
Tsc1 neuronal loss causes dysplastic neurons and seizures in models (Meikle et al., 2007, 455 citations). mTORC1 hyperactivity drives ectopic neurons, but human tuber pathology varies (Orlova and Crino, 2009, 399 citations). EEG-MRI correlation for seizure onset zones needs refinement.
Neurodevelopmental Outcome Prediction
Autism and cognitive deficits link to early seizures, with 50% TSC patients affected (Meikle et al., 2008, 499 citations). Infant screening via EEG identifies risks, but preventive interventions show variable efficacy (Jóźwiak et al., 2011, 304 citations). Biomarkers for progression remain elusive.
Essential Papers
Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
Darcy A. Krueger, Hope Northrup, Hope Northrup et al. · 2013 · Pediatric Neurology · 832 citations
Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
Jacqueline A. French, John A. Lawson, Zühal Yapıcı et al. · 2016 · The Lancet · 722 citations
Novartis Pharmaceuticals Corporation.
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
Hope Northrup, Mary E. Aronow, E. Martina Bebin et al. · 2021 · Pediatric Neurology · 630 citations
Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function
Lynsey M. Meikle, Kristen Pollizzi, Anna Egnor et al. · 2008 · Journal of Neuroscience · 499 citations
Tuberous sclerosis (TSC) is a hamartoma syndrome attributable to mutations in either TSC1 or TSC2 in which brain involvement causes epilepsy, mental retardation, and autism. We have reported recent...
A Mouse Model of Tuberous Sclerosis: Neuronal Loss of Tsc1 Causes Dysplastic and Ectopic Neurons, Reduced Myelination, Seizure Activity, and Limited Survival
Lynsey M. Meikle, Delia M. Talos, Hiroaki Onda et al. · 2007 · Journal of Neuroscience · 455 citations
Tuberous sclerosis (TSC) is a hamartoma syndrome caused by mutations in TSC1 or TSC2 in which cerebral cortical tubers and seizures are major clinical issues. We have engineered mice in which most ...
The tuberous sclerosis complex
Ksenia Orlova, Peter B. Crino · 2009 · Annals of the New York Academy of Sciences · 399 citations
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that results from mutations in the TSC1 or TSC2 genes and is associated with hamartoma formation in multiple organ systems. The ne...
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Darcy A. Krueger, Angus A. Wilfong, Katherine Holland‐Bouley et al. · 2013 · Annals of Neurology · 380 citations
Objective Epilepsy is a major manifestation of tuberous sclerosis complex (TSC). Everolimus is an mammalian target of rapamycin complex 1 inhibitor with demonstrated benefit in several aspects of T...
Reading Guide
Foundational Papers
Start with Krueger et al. (2013, 832 citations) for surveillance guidelines on seizures and tubers; Meikle et al. (2007, 455 citations) for Tsc1 mouse model establishing neuronal dysplasia-seizure links; Orlova and Crino (2009, 399 citations) for TSC1/TSC2-mTOR overview.
Recent Advances
Northrup et al. (2021, 630 citations) updated diagnostics; French et al. (2016, 722 citations) EXIST-3 everolimus trial; Jóźwiak et al. (2011, 304 citations) on preemptive therapy outcomes.
Core Methods
MRI/EEG for tuber/seizure mapping (Krueger et al., 2013); Tsc1 conditional knockout mice (Meikle et al., 2007); mTOR inhibitors like everolimus in RCTs (French et al., 2016); preventative vigabatrin in infants (Jóźwiak et al., 2011).
How PapersFlow Helps You Research Neurological Manifestations of TSC
Discover & Search
Research Agent uses searchPapers and citationGraph to map 832-cited Krueger et al. (2013) consensus to 722-cited French et al. (2016) everolimus trial, revealing epilepsy management clusters. exaSearch uncovers 50+ TSC seizure papers; findSimilarPapers links Meikle et al. (2007) mouse model to human MRI studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract seizure reduction stats from French et al. (2016), then verifyResponse (CoVe) with GRADE grading confirms 39.6% responder rate (moderate evidence). runPythonAnalysis processes EEG datasets from Krueger et al. (2013) for statistical verification of mTOR inhibitor effects via pandas seizure frequency analysis.
Synthesize & Write
Synthesis Agent detects gaps in everolimus long-term data post-French et al. (2016), flags contradictions between mouse models (Meikle et al., 2008) and human outcomes. Writing Agent uses latexEditText, latexSyncCitations for Krueger/Northrup papers, latexCompile for review manuscripts, and exportMermaid for tuber-MRI pathway diagrams.
Use Cases
"Analyze seizure frequency data from TSC everolimus trials using Python."
Research Agent → searchPapers('everolimus TSC epilepsy') → Analysis Agent → readPaperContent(French 2016) → runPythonAnalysis(pandas on responder rates, matplotlib seizure plots) → CSV export of 40% reduction stats.
"Draft LaTeX review on TSC cortical tubers and mTOR signaling."
Synthesis Agent → gap detection(Meikle 2007/2008) → Writing Agent → latexEditText(structure sections) → latexSyncCitations(Krueger 2013, Northrup 2021) → latexCompile(PDF) → researcher gets formatted manuscript with diagrams.
"Find GitHub repos analyzing TSC mouse model EEG data."
Research Agent → searchPapers('Tsc1 mouse model seizures') → paperExtractUrls(Meikle 2007) → paperFindGithubRepo → githubRepoInspect(EEG analysis scripts) → researcher gets runnable Jupyter notebooks for neuronal loss simulations.
Automated Workflows
Deep Research workflow scans 250M+ papers via OpenAlex for TSC neurology, chaining searchPapers → citationGraph → DeepScan (7-step: extract, verify, GRADE Krueger 2013 metrics). Theorizer generates hypotheses on mTOR-Akt signaling from Meikle et al. (2008), outputting mermaid diagrams of epileptogenesis pathways. DeepScan verifies Jóźwiak 2011 preventive therapy claims with CoVe across 50 papers.
Frequently Asked Questions
What defines neurological manifestations in TSC?
Cortical tubers, subependymal nodules, epilepsy in 80-90% of cases, and autism in 40-50%, caused by TSC1/TSC2 mutations disrupting mTOR signaling (Orlova and Crino, 2009).
What are key methods for studying TSC epilepsy?
MRI detects tubers, EEG localizes seizures, mouse Tsc1 models simulate neuronal loss (Meikle et al., 2007), and everolimus trials test mTOR inhibition (French et al., 2016).
What are seminal papers on TSC neurology?
Krueger et al. (2013, 832 citations) consensus guidelines; Meikle et al. (2007/2008, 455+499 citations) mouse models; French et al. (2016, 722 citations) everolimus phase 3 trial.
What open problems persist in TSC neurology?
Predicting everolimus responders, refining epileptogenic tuber identification via EEG-MRI, and scaling preventive antiepileptics to prevent 50% cognitive deficits (Northrup et al., 2021).
Research Tuberous Sclerosis Complex Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neurological Manifestations of TSC with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers